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Abstract To compare profiles of subjects with and
without cervical dystonia (CD)-associated pain, to evaluate
the contribution of pain and the motor component of CD on
quality of life, and to compare the initial botulinum toxin
treatment paradigm between pain groups, baseline data
were used from the CD Patient Registry for Observation of
OnabotulinumtoxinA Efficacy (CD PROBE), a multicen-
ter, prospective, observational registry designed to capture
real-world practices and outcomes for onabotulinumtoxinA
CD treatment. Subjects were divided into no/mild pain
[Pain Numeric Rating Scale (PNRS) score 0–3] and mod-
erate/severe pain groups (PNRS score 4–10). Descriptive
and differential statistics were utilized to compare groups.
1,037 subjects completed the first treatment session,
reported baseline botulinum toxin status, and completed
baseline PNRS. Those with no/mild pain were significantly
older at baseline. Those subjects with moderate/severe pain
had higher Toronto Western Spasmodic Torticollis Rating
Scale Severity (17.7 ± 5.1 vs. 16.2 ± 5.6, p \ 0.0001)
and Disability (12.7 ± 6.1 vs. 7.5 ± 5.6, p \ 0.0001). CD
subjects with moderate/severe pain received a higher mean
dose (177.3 ± 82.9 vs. 158.0 ± 67.1 U, p = 0.0001) of
onabotulinumtoxinA and were injected in more muscles
(4.1 ± 1.4 vs. 3.7 ± 1.2, p \ 0.0001) at initial treatment.
CD PROBE clearly demonstrates the frequency of pain in
CD and substantiates its importance when determining an
optimal treatment paradigm. Future analyses of CD
PROBE will further our understanding of the treatment
patterns and outcomes related to onabotulinumtoxinA
therapy for this disabling condition.
Keywords Botulinum toxin  Cervical dystonia 
Dystonia  Pain
Electronic supplementary material The online version of this
article (doi:10.1007/s00415-014-7343-6) contains supplementary
material, which is available to authorized users.
P. D. Charles (&)
Department of Neurology, Vanderbilt University Medical




Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
M. Stacy
Department of Neurology, Duke University Medical Center,
Durham, NC, USA
C. Comella
Department of Neurological Sciences, Rush-Presbyterian-St.
Luke’s Medical Center, Chicago, IL, USA
J. Jankovic
Department of Neurology, Baylor College of Medicine, Houston,
TX, USA
A. Manack Adams  M. F. Brin
Allergan, Inc., Irvine, CA, USA
M. Schwartz
MedNet Solutions, Inc., Minnetonka, MN, USA
M. F. Brin
School of Medicine, University of California, Irvine, CA, USA
123
J Neurol (2014) 261:1309–1319
DOI 10.1007/s00415-014-7343-6
Introduction
Cervical dystonia (CD) represents the most common form
of adult onset focal dystonia, and pain is one of its most
prevalent and disabling features [1–3]. Idiopathic CD
typically presents in midlife with insidious onset, and is a
neurological disorder with sustained involuntary neck
muscular contraction resulting in twisting and turning
movements and abnormal head and shoulder postures [3–
6]. Because oral medications rarely provide adequate
symptomatic relief without intolerable side effects, botu-
linum toxin (BoNT) injection is widely regarded as first-
line therapy for CD [7]. For those who are either no longer
adequately responding to BoNT injection, surgical inter-
ventions, including selective peripheral denervation or
deep brain stimulation, may be considered [8].
The CD Patient Registry for Observation of Onabotuli-
numtoxinA Efficacy (CD PROBE) is the largest observa-
tional study of subjects with CD. The main objectives are
to generate data to improve understanding of the demo-
graphic and clinical presentation of those suffering from
CD, as well as to define the effectiveness and safety profile
for onabotulinumtoxinA treatment [9]. Herein, we focus on
analyses related to pain, a highly debilitating feature
associated with the condition. The role of pain in CD
pathophysiology and severity is not well understood. Thus,
study analyses compare the demographic and clinical
profiles between those with no/mild and moderate/severe
CD-associated pain, evaluate the contributions of pain and
the motor component of CD on quality of life, and compare
the initial onabotulinumtoxinA treatment paradigm
between groups.
Methods
Cervical Dystonia Patient Registry for Observation of
OnabotulinumtoxinA Efficacy is a prospective, multicen-
ter, observational registry that enrolled subjects with CD
from January 12, 2009 to August 31, 2012 at 88 sites in the
United States. Since the aim was to describe the utilization
of onabotulinumtoxinA within this rare disease, the study
size was determined as the number of subjects who could
be reasonably recruited within this time frame. A com-
prehensive description of the methods of CD PROBE has
been previously published [9].
Subjects
Briefly, subjects with a physician’s diagnosis of CD were
either naı¨ve to BoNT therapy, new to the physician’s
practice, or had not received BoNT for C16 weeks if a
previous participant in a clinical trial. Subjects could be
enrolled if they met any of these inclusion criteria, which
were designed to exclude subjects who are on a stable and
optimized botulinum toxin therapy, as these subjects may
not show a great change from their condition at study
baseline. Exclusion criteria involved planning elective
surgery during the study period; pregnancy, nursing, or
planning a pregnancy; a history of non-compliance with
medical treatment; or any condition or situation that, in
investigator opinion, could place the subject at risk, con-
found the registry data, or interfere significantly with
subject participation in the registry.
Study assessments
For this analysis, subject-reported measures included the
Pain Numeric Rating Scale (PNRS), a validated, single-
item question on the current level of pain (range 0–10) [10–
12], with established cut-points of 0–3 for mild, 4–6 for
moderate, and 7–10 as severe [13, 14], and the CD Impact
Profile-58 (CDIP-58), a validated questionnaire comprised
of eight subscales (Head and Neck Symptoms, Pain and
Discomfort, Upper Limb Activities, Walking, Sleep,
Annoyance, Mood, and Psychosocial Functioning, each
ranging from 0 to 100) [15]. Subjects also completed a
work productivity questionnaire developed for this registry
[9]. Physician assessments included severity of CD (mild,
moderate, or severe, compared to the most severe CD case
seen or imagined), classification of the predominant sub-
type (anterocollis, laterocollis, retrocollis, or torticollis),
and the Toronto Western Spasmodic Torticollis Rating
Scale (TWSTRS), a CD-specific questionnaire composed
of subscales for Pain (range 0–20), Severity (range 0–35),
and Disability (range 0–30) [16]. The onabotulinumtoxinA
dose and the number of muscles injected at first treatment
were also evaluated.
Registration, protocol approvals, and subject consents
This study is registered with ClinicalTrials.gov
(NCT00836017). Each participating center obtained insti-
tutional review board approval, and written informed
consent was obtained from each subject prior to any study
procedures being performed.
Statistical analysis
The population for this analysis included those who
reported whether or not they had received previous BoNT
toxin treatment, completed the first treatment session, and
completed the PNRS at baseline. The number of subjects
with missing data is indicated in each table, and no values
were imputed for missing data. Subjects’ pain was
dichotomized into PNRS scores of 0–3 (no/mild pain) and
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4–10 (moderate/severe). The PNRS was selected as the
pain measure for these analyses because it was a commonly
used, recommended, subject-reported measure [12], there
are established cut-points [13, 14], and pain rating was
independent of any other domain (in contrast to the CDIP-
58 Pain and Discomfort subscale).
Two sample t tests and one-way analysis of variance
were used to compare continuous measures between groups
of two and three or more, respectively. Uncorrected Chi-
square analyses were used to compare categorical measures
between groups. Multinomial and logistic regression
models were used to examine the effects of pain, age, and
gender on employment status at study baseline and on
changes in employment due to CD, respectively. Linear
regression analyses assessing the relative importance of the
motor component of CD (via the TWSTRS Severity Sub-
scale) and pain (via the PNRS) to the CDIP-58 subscales
utilized R2 and Lindeman–Merenda–Gold [17] estimates,
and the threshold analyses were conducted using piecewise
linear regression. Linear regression models were used to
examine the effects of pain, age, gender, and TWSTRS
Severity on dose and the number of muscles injected. Post
hoc multiple pairwise comparisons were adjusted using the
step-up method of Hochberg [18]. For all analyses, a
p value of B0.05 was used to reject the null hypothesis for
statistical significance. All analyses were performed using
R software, version 3.0.0 or greater [19]. The Lindeman–
Merenda–Gold analyses were performed using the ‘‘rela-
impo’’ package for R [20], and the piecewise linear
regression analyses were performed using the ‘‘segmented’’
package for R [21, 22].
Results
Sociodemographic and clinical characteristics
by baseline pain status
A total of 88 centers enrolled 1,046 subjects between
January 12, 2009 and August 31, 2012. The analysis pop-
ulation includes 1,037 subjects who completed the first
treatment session, reported whether or not they had
received previous BoNT toxin treatment, and completed
the PNRS at baseline. Of those, 88.9 % (922/1,037)
reported pain related to CD at baseline (PNRS score [0),
70.7 % (733/1,037) rated their pain related to CD as
moderate or severe at baseline (PNRS score 4–10), and
29.3 % (304/1,037) had no or mild pain (PNRS score 0–3)
(Table 1). In addition, 90.6 % (863/953) of subjects
reported that CD caused neck pain or discomfort prior to
their study treatment. When comparing the no/mild and
moderate/severe pain groups, those with no/mild pain were
older (60.9 ± 14.5 vs. 56.8 ± 14.7 years, p \ 0.0001),
had higher levels of education (p = 0.0005), and signifi-
cantly differed in predominant subtype (p = 0.0150).
Subjects with moderate/severe pain at baseline reported
significantly higher usage of analgesics, antianxiety agents,
and antidepressants compared with those in the no/mild
group (p B 0.05) (Table 1). There were no significant
differences between the two groups with regard to gender,
race/ethnicity, BoNT-naı¨ve status, body mass index, or
time from CD diagnosis to treatment (Table 1).
Significant differences between the groups were dem-
onstrated when evaluating work and employment mea-
sures. Self-reported employment status differed
(p \ 0.0001) by group, with a higher percentage of those
with moderate/severe pain reporting being ‘‘disabled’’
(14.7 vs. 4.9 %; Table 1). In addition, a multinomial
regression model, in which full-time employment was the
reference level, indicated that subjects with moderate/
severe pain were nearly four times more likely to be dis-
abled as an employment status [odds ratio (OR) = 3.9;
95 % confidence interval (CI) 2.2–7.2, p \ 0.0001;
Table 2] than those with no/mild pain. Age was signifi-
cantly associated with differences in employment status at
baseline, where the most notable shift occurred at 65 years,
the standard US retirement age (Online Resource Fig. 1).
In addition, those with moderate/severe pain related to
CD were more likely to have reported stopping work due to
CD when compared with those with no/mild pain related to
CD (44.9 vs. 20.5 %, p = 0.0002; Table 1). Furthermore,
logistic regression analysis indicated that those with mod-
erate/severe pain were more than two times more likely to
have stopped work due to CD (OR = 2.2; 95 % CI
1.2–4.5, p = 0.0193) than those with no/mild pain
(Table 2; Fig. 1a). A general trend of an increased proba-
bility of work being stopped due to CD is seen with
increasing age, until a sharp decrease beginning around age
55. For those who were employed at study baseline, a
significant difference was also reported for employment
status affected by CD, with a lower percentage of those
with moderate/severe pain reporting no impact (66.1 vs.
89.3 %, p \ 0.0001; Table 1). Moderate/severe pain was a
significant predictor contributing to the probability that
employment status was affected by CD (OR = 4.5, 95 %
CI 2.6–8.3, p \ 0.0001); there was no gender-related dif-
ference (Table 2; Fig. 1b).
Clinical measures of pain
Baseline pain was assessed through multiple measures
(mean PNRS, 5.1 ± 3.0; mean TWSTRS Pain subscale,
10.5 ± 5.1; and mean CDIP-58 Pain and Discomfort sub-
scale score, 70.6 ± 22.8) (Table 3). Pain scales were found
to correlate with one another: TWSTRS Pain subscale with
the CDIP-58 Pain and Discomfort subscale (r = 0.63,
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pain (n = 733)
p value
Age (years)
Mean ± SD 58.0 ± 14.7 60.9 ± 14.5 56.8 ± 14.7 \0.0001
Data not available 0 0 0
Gender
Female 772 (74.4) 226 (74.3) 546 (74.5) 0.9608
Data not available 0 0 0
Race/ethnicity
White 959 (92.5) 285 (93.8) 674 (92.0) 0.2832
Non-Whitea 78 (7.5) 19 (6.3) 59 (8.0)
Data not available 0 0 0
BMI (kg/m2)
Mean ± SD 26.6 ± 5.4 26.4 ± 5.2 26.7 ± 5.5 0.3531
Data not available 74 24 50
Educational level
Less than a high school diploma 41 (4.0) 9 (3.0) 32 (4.4) 0.0005
High school graduate/some college 518 (50.0) 130 (42.8) 388 (52.9)
Associate/Bachelor’s degree 314 (30.3) 112 (36.8) 202 (27.6)
Advanced degree (Masters, Doctoral, Professional) 147 (14.2) 50 (16.4) 97 (13.2)
Other 17 (1.6) 3 (1.0) 14 (1.9)
Data not available 0 0 0
Employment status
Retired 339 (32.7) 116 (38.2) 223 (30.4) \0.0001
Employed full time 308 (29.7) 99 (32.6) 209 (28.5)
Employed part time 67 (6.5) 28 (9.2) 39 (5.3)
Disabled 123 (11.9) 15 (4.9) 108 (14.7)
Self-employed 61 (5.9) 19 (6.2) 42 (5.7)
Otherb 139 (13.4) 27 (8.9) 112 (15.3)
Data not available 0 0 0
Work stopped due to CDc, n (%) 107 (38.5) 15 (20.5) 92 (44.9) 0.0002
Employment status affected by CDd
No 327 (74.0) 134 (89.3) 193 (66.1) \0.0001
Yes
Different job with less responsibility/pay 28 (6.3) 5 (3.3) 23 (7.9)
Loss of employment 4 (0.9) 0 (0.0) 4 (1.4)
Reduced hours or responsibility 83 (18.8) 11 (7.3) 72 (24.7)
Severity
Mild 344 (33.2) 111 (36.5) 233 (31.8) 0.0376
Moderate 546 (52.7) 161 (53.0) 385 (52.6)
Severe 146 (14.1) 32 (10.5) 114 (15.6)
Data not available 1 0 1
CD type
Anterocollis 59 (5.7) 13 (4.3) 46 (6.3) 0.0150
Laterocollis 402 (38.8) 103 (33.9) 299 (40.8)
Retrocollis 55 (5.3) 12 (3.9) 43 (5.9)
Torticollis 493 (47.6) 164 (53.9) 329 (44.9)
Other 27 (2.6) 12 (3.9) 15 (2.0)
Data not available 1 0 1
Age at symptom onset, years
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p \ 0.0001), TWSTRS Pain subscale with the PNRS
(r = 0.78, p \ 0.0001), and the CDIP-58 Pain and Dis-
comfort subscale with the PNRS (r = 0.59, p \ 0.0001).
For each of these pain scales, we assessed if pain scores
differed by the physician’s assessment of disease severity.
There were significant differences when comparing all pain
measures across the severity subgroups (mild, moderate,
and severe) for the PNRS and TWSTRS Pain subscale
(p = 0.0004 and p = 0.0058, respectively) (Table 3). The
CD group with mild disease severity reported the lowest
mean pain scores for all instruments (mean PNRS,
4.7 ± 2.9; mean TWSTRS Pain subscale, 10.0 ± 5.2; and
mean CDIP-58 Pain and Discomfort subscale score,
69.7 ± 22.5) (Table 3). Furthermore, when evaluating the
TWSTRS Severity and Disability subscale scores by pain
status, compared with those with no/mild baseline pain,
those with moderate/severe pain had significantly higher
Severity (17.7 ± 5.1 vs. 16.2 ± 5.6, p \ 0.0001) and
Disability (12.7 ± 6.1 vs. 7.5 ± 5.6, p \ 0.0001)
(Table 4).
Pain and severity relationship with CD impact
Exploratory analyses were conducted to assess the inter-
play between pain (as measured by PNRS), the motor
component of CD (as measured by TWSTRS Severity
score), and CD impact (as measured by the CDIP-58 sub-
scales). The relationship between the TWSTRS Severity
and PNRS was not the same for each of the CDIP-58
subscales.
Figure 2 reflects how pain (measured by PNRS) and







pain (n = 733)
p value
Mean ± SD 49.0 ± 16.7 50.1 ± 17.4 48.6 ± 16.4 0.1879
Data not available 0 0 0
Time from CD onset to diagnosis (years)
Mean ± SD 5.0 ± 8.1 5.6 ± 7.1 4.7 ± 8.5 0.0704
Data not available 0 0 0
Time from CD diagnosis to treatment (years)
Mean ± SD 1.2 ± 4.5 1.6 ± 6.0 1.0 ± 3.7 0.0840
Data not available 0 0 0
Previously received BoNT treatment
n (%) 378 (36.5) 107 (35.2) 271 (37.0) 0.5890
Data not available 0 0 0
Concomitant medicationse
Vitamins and combinations 373 (36.0) 108 (35.5) 265 (36.2) 0.8482
Analgesics, miscellaneous 230 (22.2) 34 (11.2) 196 (26.7) \0.0001
Antilipidemic agents, HMG-CoA reductase inhibitors 168 (16.2) 68 (22.4) 100 (13.6) 0.0005
Antidepressants, selective serotonin reuptake inhibitors 162 (15.6) 47 (15.5) 115 (15.7) 0.9265
b-Adrenergic blocking agents 154 (14.9) 68 (22.4) 86 (11.7) \0.0001
Thyroid preparations 139 (13.4) 41 (13.5) 98 (13.4) 0.9598
Antianxiety agents, benzodiazepines and combinations 131 (12.6) 28 (9.2) 103 (14.1) 0.0327
Antidepressants, miscellaneous 123 (11.9) 21 (6.9) 102 (13.9) 0.0015
Proton pump inhibitors 119 (11.5) 43 (14.1) 76 (10.4) 0.0824
Data not available 0 0 0
Data are presented as mean ± SD or n (%)
Pain is defined by baseline score on the PNRS: 0–3 for no/mild pain and 4–10 for moderate/severe pain
BMI body mass index, BoNT botulinum toxin, CD cervical dystonia, PNRS Pain Numeric Rating Scale
a Includes Asian, Black, Hispanic, Native American, and Other
b Includes student, unemployed, homemaker, and never employed
c Asked of subjects who were unemployed at study baseline (n = 557), but who were employed when CD symptoms began (n = 278)
d Asked of subjects who were employed at study baseline (n = 442); 38 subjects had never been employed
e Reported in [10 % of subjects
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Severity subscale) impact each domain of the CDIP-58
questionnaire. With the exception of the Psychosocial
Functioning subscale, pain directly impacted the CDIP-
58 subscales in a generally linear fashion; an increase in
the pain level was associated with an increase in the
CDIP-58 subscale score. While the motor component
directly impacted some of the CDIP-58 subscales (Head
and Neck, Walking, Annoyance, and Psychosocial
Functioning subscales) in a linear fashion, it impacted
the others (Upper Limb Activities, Sleep, and Mood) in
a nonlinear fashion, with only a TWSTRS Severity score
greater than approximately 10 demonstrating an impact.
Of note, pain had a greater impact than the motor
component on Pain and Discomfort, Mood, Annoyance,
Sleep, Head and Neck, and Upper Limb Activities; pain
and the motor component more equally impacted
Walking and Psychosocial Functioning. Online Resource
Table 1 provides the relative importance and R2 values,
most of which were low; thus, modeling pain and the
motor component explains only a limited amount of
variability in each subscale score.
Based on the findings from the 3D plots presented in
Fig. 2, there appeared to be potential thresholds for when
the rate of change (slope) in the CDIP-58 domain scores
increases or decreases with respect to increasing PNRS
and/or TWSTRS Severity scores. Piecewise regression
models and subsequent evaluation of respective point
Table 2 Regression models of employment status, work stopped due
to CD, and employment status affected by CD by pain group and
gender
Odds ratio 95 % CI p value
Employment status
Employed part time
Moderate/severe pain 0.7 0.4–1.3 0.2881
Male 0.3 0.1–0.7 0.0060
Self-employed
Moderate/severe pain 1.3 0.7–2.3 0.4429
Male 1.2 0.6–2.2 0.6108
Retired
Moderate/severe pain 1.6 1.0–2.6 0.0533
Male 1.0 0.6–1.6 0.9333
Disabled
Moderate/severe pain 3.9 2.2–7.2 \0.0001
Male 1.5 1.0–2.5 0.0799
Othera
Moderate/severe pain 2.2 1.3–3.6 0.0028
Male 0.6 0.3–1.0 0.0328
Work stopped due to CDb
Moderate/severe pain 2.2 1.2–4.5 0.0193
Male 1.2 0.7–2.2 0.4599
Employment status affected by CDc
Moderate/severe pain 4.5 2.6–8.3 \0.0001
Male 1.1 0.6–1.8 0.8413
All values are compared with the reference of no/mild pain and
female gender
Age was modeled using a cubic spline transformation with 4 df (three
interior knots) to allow for a curvilinear relationship, and is thus not
depicted in this table
CD cervical dystonia, CI confidence interval
a Includes student, unemployed, homemaker, and never employed
b For those who were unemployed at the time of study enrollment but
were employed when CD symptoms began
c For those who were employed at the time of study enrollment
20 30 40 50 60 70 80
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Mod/Severe Pain + Female
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No/Mild Pain + Female
Mod/Severe Pain + Female
No/Mild Pain + Male
Mod/Severe Pain + Male
Fig. 1 Effects of pain group, age, and gender on the a probability of
work being stopped due to CD and b the probability of employment
status being affected by CD. Patients had to be employed at time of
CD diagnosis for these logistic regression models. CD cervical
dystonia
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estimates and CIs were conducted to determine likely
threshold estimates for each CDIP-58 subscale. As suggested
in the 3D plots, piecewise regression models indicated that
likely thresholds were not present for every subscale. How-
ever, likely thresholds were demonstrated for PNRS in the
subscale of Pain and Discomfort, with a threshold score or
point estimate of 6.64 (95 % CI 5.74–7.55), and for TWSTRS
Severity scores in the subscales of Upper Limb Activities,
21.83 (95 % CI 19.91–23.75); Walking, 19.05 (95 % CI
14.92–23.18); Sleep, 25.11 (95 % CI 20.67–29.55); and
Mood, 25.57 (95 % CI 22.75–28.38). For all other subscales,
potential thresholds were determined to be not estimable or
unlikely to possible.
OnabotulinumtoxinA treatment utilization
CD subjects with moderate/severe pain at baseline were
given a significantly higher mean dose of onabotulinum-
toxinA at treatment session 1 compared with those with no/
mild pain (177.3 ± 82.9 vs. 158.0 ± 67.1 U, p \ 0.0001).
Similarly, subjects reporting moderate/severe pain at
baseline were injected in a greater number of muscles
(4.1 ± 1.4 vs. 3.7 ± 1.2, p \ 0.0001) (Table 5).
Different treatment patterns were demonstrated when
comparing treatment-naı¨ve and non-naı¨ve groups by pain
status. For both the naı¨ve and non-naı¨ve cohorts, subjects
with moderate/severe pain received higher doses of onab-
otulinumtoxinA compared with subjects with no/mild pain
(p \ 0.0001 for each). When comparing within the naı¨ve
groups, a significantly higher dose of onabotulinumtoxinA
at treatment session 1 was administered to those CD sub-
jects with moderate/severe pain compared with those with
no/mild pain at baseline (151.6 ± 64.9 vs.
136.6 ± 56.6 U, p = 0.0216) (Table 5). The number of
muscles injected also was significantly greater in those
with moderate/severe pain at baseline who were naı¨ve
compared with those with no/mild pain who were naı¨ve
(4.0 ± 1.3 vs. 3.5 ± 1.2, p \ 0.0001) (Table 5). In con-
trast, a different pattern was seen when comparing the non-
naı¨ve groups by pain status. The mean dose was higher in
the non-naı¨ve subgroup with moderate/severe pain com-
pared with those with no/mild pain (218.3 ± 91.7 vs.
198.9 ± 67.0 U, p = 0.0216) (Table 5), but the number of
muscles injected was not significantly greater in those who
were non-naı¨ve and had moderate/severe pain compared
with those with no/mild pain (4.2 ± 1.4 vs. 4.0 ± 1.2 U,
p = 0.7402) (Table 5).
Table 3 Pain scores at baseline
by physician-assessed severity
Data are presented as
mean ± SD or n (%)
Scales range as follows: Pain
Numeric Rating Scale, 0–10;
TWSTRS Pain subscale, 0–20;
and CDIP-58 Pain and
Discomfort subscale, 0–100
CDIP-58 Cervical Dystonia
Impact Profile, PNRS Pain
Numeric Rating Scale, TWSTRS
Toronto Western Spasmodic
Torticollis Rating Scale
a Severity data were











n 1,036 344 546 146
Mean ± SD 5.1 ± 3.0 4.7 ± 2.9 5.2 ± 3.0 5.9 ± 2.9 0.0004
Data not
available
0 0 0 0
TWSTRS Pain subscale
n 1,034 344 544 146
Mean ± SD 10.5 ± 5.1 10.0 ± 5.2 10.5 ± 5.0 11.6 ± 5.1 0.0058
Data not
available
2 0 2 0
CDIP-58 Pain and Discomfort subscale
n 1,027 344 538 145
Mean ± SD 70.6 ± 22.8 69.7 ± 22.5 70.2 ± 23.3 74.6 ± 21.3 0.0545
Data not
available
9 0 8 1
Table 4 TWSTRS subscale and total scores by the presence of pain











Severity 17.3 ± 5.3 16.2 ± 5.6 17.7 ± 5.1 \0.0001
Disability 11.1 ± 6.4 7.5 ± 5.6 12.7 ± 6.1 \0.0001
Pain 10.5 ± 5.1 5.1 ± 4.2 12.7 ± 3.5 \0.0001




Data are presented as mean ± SD or n (%)
Pain is defined by baseline score on the PNRS: 0–3 for no/mild pain
and 4–10 for moderate/severe pain
Scales range as follows: Severity, 0–35; Disability, 0–30; Pain, 0–20;
and Total, 0–85
PNRS Pain Numeric Rating Scale, TWSTRS Toronto Western Spas-
modic Torticollis Rating Scale
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A linear regression model to examine the contributions
of pain, age, gender, and severity (as measured via
TWSTRS) on predicted onabotulinumtoxinA dose showed
that subjects with moderate/severe pain received on aver-
age of 14 more units than subjects with no/mild pain
(13.9 U; 95 % CI 3.1–24.7, p = 0.0114) (Table 6). Gender
also significantly impacted dose, with males receiving
nearly 15 more units than females (14.6 U; 95 % CI
3.4–25.8, p = 0.0109). Online Resource Fig. 2 shows that

































































































































































































































































































Fig. 2 Influence of TWSTRS Severity score and PNRS score on
CDIP-58 subscale scores. Lindeman–Merenda–Gold estimates and a
piecewise natural cubic spline were used to generate each 3D
perspective plot. Dashed line indicates the front of the cube for each
plot; CDIP-58 Cervical Dystonia Impact Profile-58, PNRS Pain
Numeric Rating Scale, TWSTRS Toronto Western Spasmodic Torti-
collis Rating Scale
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scores, and that males with moderate/severe pain received
the highest doses. A similar analysis conducted for number
of injected muscles showed that subjects with moderate/
severe pain were injected in 0.3 more muscles than subjects
with no/mild pain (0.31 muscles; 95 % CI 0.13–0.49,
p = 0.0008) (Table 6).
Discussion
While the association of pain with CD has been previously
described [23], the results obtained from this large cohort
study clearly highlight the impact of pain upon the per-
ceived severity, treatment paradigm, and potential effect
upon work and employment.
The CD PROBE population is comparable with the CD
populations from previously published literature, with the
majority of subjects being female (74.4 %) and experi-
encing disease onset in the fifth decade of life (mean age of
49 years) [24–29]. Subjects experiencing moderate/severe
pain at baseline were significantly younger than those with
no/mild pain, but there was no difference in the age of
symptom onset or duration of symptoms before diagnosis
or treatment.
Another important finding, which should be further
explored in additional analyses of CD PROBE, was the
impact of CD on work and employment. A higher per-
centage of those with moderate/severe pain reported being
disabled (though subjects could be on disability for reasons
other than CD) and were more likely to have stopped work
due to CD. Multinomial and logistic regression models
showed that moderate/severe pain impacted employment
status. Employment status and the effect of CD on
employment are similar to results from other chronic pain
populations [30–32]. The findings from CD PROBE
Table 5 Total dose (U) and number of muscles treated at first treatment session by pain and botulinum-naı¨ve treatment status at baseline
No/mild pain Moderate/
severe pain











Total dose, U (N = 973)a
Subjects, n 292 681 192 419 100 262
Mean ± SD 158.0 ± 67.1 177.3 ± 82.9 0.0001 136.6 ± 56.6 151.6 ± 64.9 0.0216 198.9 ± 67.0 218.3 ± 91.7 0.0216
Min, max 15.0, 400.0 15.0, 500.0 15.0, 346.0 15.0, 407.0 45.0, 400.0 40.0, 500.0




– – 135.5 152.1 201.0 217.5
Total number of muscles (N = 1,036)b
Subjects, n 303 733 196 462 107 271
Mean ± SD 3.7 ± 1.2 4.1 ± 1.4 \0.0001 3.5 ± 1.2 4.0 ± 1.3 \0.0001 4.0 ± 1.2 4.2 ± 1.4 0.7402
Min, max 1.0, 7.0 1.0, 11.0 1.0, 7.0 1.0, 10.0 1.0, 7.0 1.0, 11.0




– – 3.6 4.0 3.9 4.2
Pain is defined by baseline score on the PNRS: 0–3 for no/mild pain and 4–10 for moderate/severe pain
PNRS Pain Numeric Rating Scale
a Dosing information was unavailable for 64 subjects
b The number of muscles injected was unavailable for 1 subject
Table 6 Dose (U) and number of muscles treated at first treatment
session by pain group, age, gender, and TWSTRS Severity
Estimate 95 % CI p value
Dose, Ua
Moderate/severe pain 13.90 3.14, 24.66 0.0114
Age (years) -0.48 -0.81, -0.14 0.0051
Male 14.56 3.36, 25.75 0.0109
TWSTRS Severity Score 2.33 1.41, 3.25 \0.0001
Muscles injected, nb
Moderate/severe pain 0.31 0.13, 0.49 0.0008
Age (years) -0.01 -0.01, -0.00 0.0051
Male -0.25 -0.44, -0.06 0.0089
TWSTRS Severity Score 0.03 0.01, 0.04 0.0004
All values are compared with the reference of no/mild pain and
female gender
CI confidence interval, TWSTRS Toronto Western Spasmodic Torti-
collis Rating Scale
a Adjusted R2 = 0.0502
b Adjusted R2 = 0.0354
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indicate a significant burden to society when considering
the impact of CD related to lost employment and work
productivity from approximately 50 cases per million
people worldwide suffering from CD [2].
The large majority of CD PROBE subjects were expe-
riencing pain at baseline, which is consistent with other
findings [24, 33, 34]. In two large prior studies of subjects
with CD, the frequency of pain was 68 % [34] and 75 %
[24], respectively. In this study, pain correlated with the
perceived severity of CD as reported by the physician and
the TWSTRS Severity and Disability subscales. These
results indicate that pain correlates with disease severity,
but that this relationship is complex, as it is not clear
whether pain directly contributes to an increase in severity
or if pain arises as a consequence of increased severity.
Furthermore, these should not be considered mutually
exclusive because pain may have differential impact for
individual subjects. The correlations presented here
explained only a limited amount of the variability in the
CDIP-58 subscales, and future work could focus on iden-
tifying other contributing factors. As well, additional epi-
demiological studies are needed to better define the
potential relationship by examining the temporal
sequencing and interaction between pain and severity.
With regard to treatment, subjects with moderate/severe
pain received injection in more muscles and a higher
overall dose of onabotulinumtoxinA at the first injection.
Moderate/severe pain, male gender, and increasing
TWSTRS Severity score led to significantly higher doses at
the first treatment session. However, it should be noted that
these models predict only 4–5 % of the variation, so factors
not identified in this analyses also influence onabotuli-
numtoxinA doses. When exploring the subpopulation who
were toxin-naı¨ve at baseline, those who were naı¨ve to toxin
also received a significantly lower dose at the first treat-
ment session. However, the dose used at first injection for
toxin-naı¨ve patients is, to a degree, based on clinical
judgment with regard to the potential concern of adminis-
tering a new treatment, and thus doses at first treatment
may not reflect an optimized treatment paradigm. Addi-
tional analyses of CD PROBE will explore how the treat-
ment paradigm is adjusted over time and whether pain is
impacted over multiple treatments.
There are several strengths related to this registry: the
prospective, observational nature reflects current real-
world practice, safety, and effectiveness; the large sample
of CD subjects; and the use of multiple outcome measures,
including those assessed by subjects and physicians. The
pain scales used in this study significantly correlated with
each other (though further convergent validity was not
performed, as it is beyond the scope of this paper). There
are also several limitations related to this registry. By
design, registry studies are not blinded or randomized and
lack control groups for comparison. CD PROBE did not
capture the nature and pattern of pain, and it was assumed
that reported neck pain was due to CD. Subgroup sample
sizes differed, especially for naı¨ve and non-naı¨ve sub-
groups, which may impact the ability to interpret signifi-
cance. Finally, depression status, the contribution of
cervical spondylosis, and the history of injury, potentially
important moderating variables, were not assessed.
Conclusions
The results of CD PROBE more clearly elucidate the
occurrence of pain and its impact upon work and treatment
patterns. Most subjects report pain at baseline, and it corre-
lates with CD severity and disability, including work and
employment measures. Therefore, pain must be considered
as an important factor when determining the dose and mus-
cles injected. CD PROBE subjects with moderate/severe
pain at baseline received a significantly higher mean dose
and had a greater number of muscles injected upon initial
treatment. Future analyses of CD PROBE will further our
understanding of the treatment patterns and outcomes related
to onabotulinumtoxinA therapy for this disabling condition.
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